Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 Data - Graham Number

Live News

As of April 23, 2026, two key near-term catalysts have shifted investor sentiment for Amgen ahead of its upcoming quarterly earnings print. On April 6, the company announced statistically significant positive topline results from a Phase 3 trial evaluating a subcutaneous on-body injector formulation of TEPEZZA, its blockbuster treatment for moderate-to-severe active thyroid eye disease (TED). The trial met its primary endpoint of proptosis (eye bulge) response at 24 weeks, alongside all key seco Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataMany traders have started integrating multiple data sources into their decision-making process. While some focus solely on equities, others include commodities, futures, and forex data to broaden their understanding. This multi-layered approach helps reduce uncertainty and improve confidence in trade execution.Investors these days increasingly rely on real-time updates to understand market dynamics. By monitoring global indices and commodity prices simultaneously, they can capture short-term movements more effectively. Combining this with historical trends allows for a more balanced perspective on potential risks and opportunities.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataScenario planning based on historical trends helps investors anticipate potential outcomes. They can prepare contingency plans for varying market conditions.

Key Highlights

Three core takeaways stand out for current and prospective AMGN investors. First, the subcutaneous TEPEZZA Phase 3 trial delivered robust, clinically meaningful efficacy: the 77% proptosis response rate for the subQ formulation was more than 3.9 times the 19.6% rate recorded for the placebo arm, with a mean 3.17mm reduction in eye bulge versus 0.80mm for placebo. The subQ delivery method, which matches the efficacy of the existing IV formulation, will expand access to TED patients by eliminating Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataExperts often combine real-time analytics with historical benchmarks. Comparing current price behavior to historical norms, adjusted for economic context, allows for a more nuanced interpretation of market conditions and enhances decision-making accuracy.Observing market correlations can reveal underlying structural changes. For example, shifts in energy prices might signal broader economic developments.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataCombining global perspectives with local insights provides a more comprehensive understanding. Monitoring developments in multiple regions helps investors anticipate cross-market impacts and potential opportunities.

Expert Insights

From a fundamental analysis perspective, Amgen’s near-term risk-reward profile is balanced, supporting Guggenheim’s Neutral rating even as the stock screens as undervalued relative to historical and peer benchmarks. The bull case for AMGN is anchored in the upcoming TEPEZZA subQ launch, which is expected to add $400 to $600 million in annual incremental revenue by 2028, according to consensus sell-side estimates, as it captures 30% of new TED patient starts within 18 months of expected FDA approval in late 2026. Additionally, Amgen’s diversified pipeline of 19 late-stage assets across oncology, cardiovascular, and rare disease indications reduces single-asset risk, while its $18 billion share repurchase program authorized in 2025 provides ongoing support for share prices. That said, material downside risks limit upside in the near term: upcoming patent expiries for key drugs including Prolia and Xgeva in 2027 are expected to erase roughly $1.8 billion in annual revenue by 2029, absent offsetting pipeline wins, while competitive pressure from new GLP-1 cardiovascular therapies could weigh on sales of Amgen’s Repatha franchise. Guggenheim’s $351 price target implies a 4.8% upside from AMGN’s April 23 closing price of $334.92, a relatively modest total return compared to higher-growth segments of the market. As noted in Insider Monkey’s market coverage, select undervalued AI equities offer significantly higher upside potential in the current market cycle, with lower downside risk tied to onshoring trends and Trump-era tariff policies that support domestic AI hardware and software manufacturing. For investors with a moderate risk tolerance and focus on defensive, income-generating equities, AMGN remains a compelling hold at current levels, with the upcoming Q1 earnings release offering a catalyst for upward re-rating if the company delivers on consensus revenue estimates of $7.2 billion and adjusted EPS of $4.52. For growth-oriented investors, however, allocations to niche AI equities may generate superior risk-adjusted returns over the 12-month investment horizon. Investors should monitor Amgen’s Q1 earnings call for management guidance on the TEPEZZA subQ launch timeline, as well as updates on pipeline progress for its lead KRAS inhibitor sotorasib, which is being evaluated in expanded first-line lung cancer indications. Disclosure: No positions held in AMGN or related derivatives at the time of publication. (Word count: 1172) Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataHistorical patterns still play a role even in a real-time world. Some investors use past price movements to inform current decisions, combining them with real-time feeds to anticipate volatility spikes or trend reversals.The increasing availability of commodity data allows equity traders to track potential supply chain effects. Shifts in raw material prices often precede broader market movements.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataReal-time alerts can help traders respond quickly to market events. This reduces the need for constant manual monitoring.